Five patents currently held, every record listed here
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2033. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2033
Next term end
4
Patent families
When these terms end
Each bar runs from grant to computed term end. 2015 to 2038.20202025203020352038
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
11 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Oct 2037 · Medium confidence
Also notable
Ends Jun 2033 · High confidence
Also notable
Ends Jun 2033 · High confidence
Topical Compositions and Methods of Use Thereof
US 11,260,035
The most cited patent in this portfolio, cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ophthalmic Lipophilic Drug Delivery Vehicle Formulations
US 8,999,938
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2033.
Contact Lens Cleaning Compositions
US 8,933,006
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Drug Vehicle Compositions and Methods of Use Thereof | 2 in force | to Oct 2037 |
| Ophthalmic Lipophilic Drug Delivery Vehicle Formulations | 1 in force | to Jun 2033 |
| Contact Lens Cleaning Compositions | 1 in force | to Jun 2033 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,933,006 | Contact Lens Cleaning Compositions In force · High confidence | In force | High confidence | |
| US 8,999,938 | Ophthalmic Lipophilic Drug Delivery Vehicle Formulations In force · High confidence | In force | High confidence | |
| US 11,583,496 | Drug Vehicle Compositions and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,260,035 | Topical Compositions and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,918,586 | Topical Compositions and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 1 patent in force now held by others · 3 patents ended · 11 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed